Ultime notizie per Allakos (NASDAQ:ALLK) Azioni

Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Allakos Inc

Allkem Ltd

News

PSTV

Plus Therapeutics And SpectronRx Announced The Signing Of A Manufacturing Services Agreement For The Production Of Rhenium (186Re) Obisbemeda, An Innovative Radiotherapy For CNS Cancers, Including Leptomeningeal Metastases And Recurrent Glioblastoma

Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(1.99) by 38.19 percent. The company reported quarterly sales of $302.000 thousand which beat the analyst consensus estimate of $296.000 thousand by 2.03 percent. This is a 35.47 percent decrease over sales of $468.000 thousand the same period last year.

Earnings

Earnings Beats

Earnings Misses

PRAX

Praxis Precision Medicine Q3 2024 GAAP EPS $(2.75) Misses $(1.99) Estimate, Sales $302.000K Beat $296.000K Estimate

Full Year 2024 Financial Guidance&nbsp; Guidance Issued November 6, 2024 Guidance Issued July 31, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion $1.50 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 $6.60 - $6.70

Guidance

LNTH

Lantheus Narrows 2024 Guidance: Now Sees Revenue Of $1.51B-$1.52B (Prior $1.50B-$1.52B) Vs. $1.52B Est., And Adj. EPS Of $6.65-$6.70 (Prior $6.60-$6.70) Vs. $6.66 Est.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) with a Buy and raises the price target from $18 to $20.

Price Target

Analyst Ratings

TRDA

HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Raises Price Target to $20

eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.28) by 14.84 percent. The company reported quarterly sales of $58.409 million which missed the analyst consensus estimate of $58.557 million by 0.25 percent. This is a 9.75 percent decrease over sales of $64.718 million the same period last year.

EHTH

eHealth Q3 2024 Adj. EPS $(1.47) Misses $(1.28) Estimate, Sales $58.409M Miss $58.557M Estimate

For the fourth quarter of 2024, the Company expects revenues to be in the range of $58 million to $63 million and adjusted EBITDA margin between 12% to 16%.

KRNT

Kornit Digital Expects Q4 2024 Revenues Of $58M-$63M Vs. $50.468M Consensus; Sees Adjusted EBITDA Margin Of 12% to 16%

OESX

Orion Expects FY25 Revenue Growth Outlook Of Approximately 10% And Expects Second Half Revenue To Be More Weighted To The Fourth Quarter

eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) affirms FY2024 sales outlook from $470.00 million-495.00 million to $470.00 million-495.00 million.

eHealth Affirms FY2024 Sales Guidance to $470.00M-495.00M  VS Est. 483.54M

Morgan Stanley analyst Thomas Yeh maintains Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) with a Overweight and lowers the price target from $9 to $8.

LION

Morgan Stanley Maintains Overweight on Lionsgate Studios, Lowers Price Target to $8

Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) reported quarterly earnings of $0.41 per share. This is a 22.64 percent decrease over earnings of $0.53 per share from the same period last year. The company reported $111.92 million in sales this quarter. This is a 10.47 percent decrease over sales of $125.00 million the same period last year.

Genie Energy Q3 EPS $0.41 Down From $0.53 YoY, Sales $111.92M Down From $125.00M YoY

Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.07 by 57.14 percent. The company reported quarterly sales of $50.732 million which beat the analyst consensus estimate of $50.468 million by 0.52 percent. This is a 14.34 percent decrease over sales of $59.224 million the same period last year.

Kornit Digital Q3 2024 Adj. EPS $0.11 Beats $0.07 Estimate, Sales $50.732M Beat $50.468M Estimate

Barclays analyst Jiong Shao initiates coverage on Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) with a Overweight rating and announces Price Target of $16.

Initiation

Barclays Initiates Coverage On Tencent Music Enter Gr with Overweight Rating, Announces Price Target of $16

MCFT

MasterCraft Boat Hldgs Q1 2025 Adj. EPS $0.12 Beats $0.03 Estimate, Sales $65.400M Beat $61.181M Estimate

Morgan Stanley analyst James Faucette maintains Broadridge Financial Soln (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Equal-Weight and raises the price target from $200 to $207.

Morgan Stanley Maintains Equal-Weight on Broadridge Financial Soln, Raises Price Target to $207

Brink's Q3 2024 Adj. EPS $1.51 Misses $1.79 Estimate, Sales $1.260B Miss $1.275B Estimate

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. The company reported quarterly sales of $19.361 million which missed the analyst consensus estimate of $22.161 million by 12.64 percent. This is a 5.95 percent decrease over sales of $20.586 million the same period last year.

Orion Energy Sys Q2 2025 GAAP EPS $(0.11) Misses $(0.07) Estimate, Sales $19.361M Miss $22.161M Estimate

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $0.02 by 650 percent. This is a 73.17 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $7.12 million by 38.95 percent. This is a 53.18 percent decrease over sales of $9.28 million the same period last year.

ACRS

Aclaris Therapeutics Q3 2024 GAAP EPS $(0.11) Misses $0.02 Estimate, Sales $4.35M Miss $7.12M Estimate

On Wednesday, Janover Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) announced its financial results for the third quarter ended September 30, 2024.
Revenue for the three months ended September 30, 2024, was approximately $619,000, up 6% from the previous year. Revenue increased sequentially by approximately 40%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41710716/exclusive-janover-scores-new-deal-with-real-estate-firm-for-ai-client-engagement-tools" rel="noreferrer noopener">EXCLUSIVE: Janover Scores New Deal With Real Estate Firm For AI Client Engagement Tools</a>
During fiscal 2024, Janover focused on more considerable loan opportunities, which should increase its average loan size.
With the acquisition of Groundbreaker and the recent launch of Insurtech, an increasing portion of Janover&#8217;s total revenue will be recurring revenue, where it will receive annual, quarterly, and monthly subscriptions, as well as yearly insurance premium commissions.
For the quarter ended September 30, 2024, approximately 22% of Janover&#8217;s total revenue was recurring revenue compared to 20% Q/Q. The company said it will continue to migrate its revenue to recurring and subscription revenue for the remainder of fiscal 2024 and beyond.&nbsp;&nbsp;
Subscription revenue was approximately $134,000 for the September 30, 2024 quarter, increasing sequentially by approximately 51%. Janover&#8217;s annual recurring revenue run rate reached roughly $480,000 for the September 30, 2024 quarter.&nbsp;
ARR increased sequentially by approximately 58%. ARR represents an annualization of its recurring revenue, which assumes a full year of revenue.
Net loss for the three months ended September 30, 2024, was approximately $471,000, a decrease of approximately 70%. Net loss for the three months ended September 30, 2024, decreased sequentially by approximately 41%.
Quarterly Business Highlights:
<ul>
<li>Janover Pro: Launched as a matching tool for commercial real estate loans, connecting professionals with over 1,000 lenders, including more than 10% of U.S. banks.</li>
<li>Janover Insurance Group: Achieved another profitable quarter, with run rate recurring revenue increasing by 89% quarter-over-quarter.</li>
<li>Janover Engage: Initiated the pilot of an equity marketplace connecting real estate syndicators and over 40,000 accredited investors who have collectively invested more than $1 billion.</li>
<li>Janover Connect: Rebranded and relaunched as the user-friendly real estate syndication software and investor portal for syndicators and GPs.</li>
<li>Janover Capital Markets: The debt placement team set a new revenue record for new business revenue in a single quarter.</li>
<li>Janover AI: Its conversational AI applications are now licensed by two publicly traded companies to enhance operational efficiency.</li>
</ul>
Janover&#8217;s CEO, Blake Janover, highlighted a milestone quarter, noting it as the strongest since their IPO and marking a third consecutive period of simultaneous gains in revenue, net income, cash flow, adjusted EBITDA, and ARR.
Price Action: JNVR stock closed higher by 3.82% at $0.5623 at Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41043484/exclusive-janover-enhances-insurtech-subsidiary-with-ai-powered-sales-and-engagement-tools" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Janover Enhances Insurtech Subsidiary with AI-Powered Sales and Engagement Tools</a></li>
</ul>

Fintech news covering the emerging Financial Technology services sector

Fintech

Exclusives

Tech

JNVR

EXCLUSIVE: Janover's Q3 Revenue Rises 6%, CEO Eyes Boost in Recurring Sales and Larger Loans

Market-Moving Exclusives

Janover Q3 2024 Revenue $618.7K Vs $583.76K YoY, EPS $(0.04) Vs $(0.17) YoY

2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">Q4 2024 Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">FY 2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">Baseline</td>
<td colspan="1" rowspan="1">High</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">Baseline</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$1.850B</td>
<td colspan="1" rowspan="1">$1.870B</td>
<td colspan="1" rowspan="1">$1.890B</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$7.390B</td>
<td colspan="1" rowspan="1">$7.410B</td>
<td colspan="1" rowspan="1">$7.430B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA&#x2A;1</td>
<td colspan="1" rowspan="1">$478M</td>
<td colspan="1" rowspan="1">$488M</td>
<td colspan="1" rowspan="1">$498M</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1.885B</td>
<td colspan="1" rowspan="1">$1.895B</td>
<td colspan="1" rowspan="1">$1.905B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA Margin&#x2A;1</td>
<td colspan="1" rowspan="1">25.8%</td>
<td colspan="1" rowspan="1">26.1%</td>
<td colspan="1" rowspan="1">26.3%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">25.5%</td>
<td colspan="1" rowspan="1">25.6%</td>
<td colspan="1" rowspan="1">25.6%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. Earnings per Share&#x2A;1</td>
<td colspan="1" rowspan="1">$0.70</td>
<td colspan="1" rowspan="1">$0.71</td>
<td colspan="1" rowspan="1">$0.72</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.65</td>
<td colspan="1" rowspan="1">$2.66</td>
<td colspan="1" rowspan="1">$2.67</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890M</td>
<td colspan="1" rowspan="1">$920M</td>
<td colspan="1" rowspan="1">$940M</td>
</tr>
</tbody>
</table>
</figure>

Howmet Aerospace Sees Q4 Revenue Of $1.85B-$1.89B Vs. $1.89B Est.; Adj. EPS Of $0.70-$0.72 Vs. $0.69 Est.

Allakos perks up after early-stage data for lead asset

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Allakos (ALLK – Research Report), Edwards Lifescie...

Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)

Jasper gains 11% on data for briquilimab in urticaria

Warning: ALLK is at high risk of performing badly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AKBA

ALLK

APVO

CLDX

CNSP

CRMD

CYCC

DBVT

GNPX

IMUX

JSPR

MBIO

NAMS

ONCT

REGN

SGMO

SLRN

SPRY

SYRS

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc.  - ALLK

Legal

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

General

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Health Care

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Comments

Allakos

Notizie

Ultime notizie per Allakos (NASDAQ:ALLK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO